NCT04466137 2022-02-09Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving ChemotherapyXiamen Amoytop Biotech Co., Ltd.Phase 3 Completed398 enrolled